期刊文献+

RP—HPLC法测定大剂量化疗时人血浆中甲氨喋呤浓度 被引量:2

Determination of methotrexate in high dose chemical therapy in human plasma by RP-HPLC
下载PDF
导出
摘要 目的 建立大剂量化疗时人血浆中甲氨喋呤浓度的测定方法。方法 采用反相高效液相色谱法(RP—HPLC)。色谱柱:μ Bondapak C18(4.6×150mm),柱温:35℃,流动相为甲醇:(pH7.2)磷酸缓冲液(17:83,v/v),流速:1.0ml·min^-1,检测波长306nm。结果 线性范围0.08~100μg·ml^-1,线性关系良好,r=0.9999,最低检测浓度0.01μg·ml^-1,回收率102.0%,日内及日间RSD均〈5%。结论 该方法简单快捷、灵敏度高、结果准确,适用于大剂量化疗时甲氨喋呤血药浓度监测。 Objective To establish the method to determine of methotrexate in chemical therapy in hunan plasma. Methods The concentration of MTX the sample was determined by RP HPLC. μ Bondapak C18(4.6×150mm) was used. The mobile phase consisted of methanol:( pH7. 2)phosphate solution (17:83, V/V).at a flow rate of 1.0 ml·min^-1.The column temperature was 35 ℃ and wavelength was set at 306nm. Results Good linearity was shown over the concentration range of 0.08-100 μ g·ml^-1(r=0.9999).The minimal detectable methotrexate drug concentration was 0.01μg·ml^-1.The average recovery was 102.0%.The relative standard deviatin of within day and between day were less than 5%.Conclusion This method is concise, convenient, high sensitive and accurate to monitor the concentration of MTX in plasma.
作者 向芳 曾东向
出处 《国际医药卫生导报》 2008年第10期76-79,共4页 International Medicine and Health Guidance News
关键词 甲氨喋呤 血药浓度 反相高效液相色谱法 Methotrexate Plasma concentration RP HPLC
  • 相关文献

参考文献3

二级参考文献29

  • 1McCrudden EA, Tett SE. Improved high-performance liquid chrornatography determination of methotrexate and its major metabolite in plasma using a poly ( styrene-divinylbenzene ) column [ J ]. J Chromatogr B Biomed Sci Appl, 1999, 721 (1) : 87.
  • 2Wang F, Jiang XG, Lu W. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats [J]. Int J Pharm. 2003.263 ( 1 ) : 1.
  • 3Chou KJ, Donovan MD. Distribution of antihistamines into the CSF following intranasal delivery[J]. Biopharm Drug Dispos, 1997, 18(4):335.
  • 4Gulyaev AE, Gelperina SE, Skind IN, et al. Significant transport of doxorubicin into the brain with polysorbate-80-coated nanoparticles[J].Pharm Res, 1999,16(10) : 1564.
  • 5SYNOLD T W, RELLING M V, BOYETT J M,et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage,ploidy,and methotrexate dose in acute lymphoblastic leukemia[J]. Clin Invest, 1994,94(5) : 1996-2001.
  • 6DELEPINE N, DELEPINE G,JASMIN C, et al. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas[J]. Biomed Pharmacother,1988,42(2) :257-262.
  • 7GRAF N, WINKLER K, BETLEMOVIC M,et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma[J]. Clin Oncol, 1994,12(7) : 1443-1451.
  • 8BACCI G, FERRARI S, DELEPINE N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high dose methotrexate, doxorubicin, and cisplatin[J]. Clin Oncol, 1998,16(2) :658-663.
  • 9ZELCER S, KELLICK M,WEXI.ER L H,et al. Methotrexate levels and outcome in osteosarcoma[J]. Pediatr Blood Cancer,2005,44(7) :638-642.
  • 10BACCI G, LORO L, LONGHI A, et al. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma[J]. Anticancer Drugs ,2006 , 17(4) :411-415.

共引文献14

同被引文献7

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部